BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Anitocabtagene autoleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Anitocabtagene autoleucel\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05396885-3142@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Anitocabtagene autoleucel: Phase 2 readout est. (NCT05396885)
DESCRIPTION:Anitocabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Mye
 loma (iMMagine-1)\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05396885
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045909-3142@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Anitocabtagene autoleucel: Phase 2 readout est. (NCT07045909)
DESCRIPTION:Anitocabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  Efficacy and Safety of Anitocabtagene Autoleucel in Participants With New
 ly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)\nEstimated primary completi
 on: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/an
 itocabtagene-autoleucel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07045909
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413498-3142@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Anitocabtagene autoleucel: Phase 3 readout est. (NCT06413498)
DESCRIPTION:Anitocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy i
 n Participants With Relapsed/ Refractory Multiple Myeloma\nEstimated prima
 ry completion: July 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/anitocabtagene-autoleucel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06413498
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06626919-3142@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Anitocabtagene autoleucel: Phase 1 readout est. (NCT06626919)
DESCRIPTION:Anitocabtagene autoleucel\, phase 1.\nStudy: Study of Anitocabt
 agene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Dis
 eases\nEstimated primary completion: October 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06626919
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903506-3142@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20390331
DTEND;VALUE=DATE:20390401
SUMMARY:Anitocabtagene autoleucel: Phase 3 readout est. (NCT07903506)
DESCRIPTION:Anitocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autol
 ogous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma\nEstimated 
 primary completion: March 2039. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/anitocabtagene-autoleucel#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07903506
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887672-3142@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20420228
DTEND;VALUE=DATE:20420301
SUMMARY:Anitocabtagene autoleucel: Phase 3 readout est. (NCT07887672)
DESCRIPTION:Anitocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Vers
 us Standard of Care in Newly Diagnosed Multiple Myeloma\nEstimated primary
  completion: February 2042. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/anitocabtagene-autoleucel#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07887672
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
